Taychakhoonavudh Suthira, Chumchujan Woralak, Hutubessy Raymond, Chaiyakunapruk Nathorn
Department of Social and Administrative Pharmacy, Faculty of Pharmaceutical Sciences, Chulalongkorn University , Bangkok, Thailand.
Immunization, Vaccines and Biologicals (IVB) Department, World Health Organization , Geneva, Switzerland.
Hum Vaccin Immunother. 2020 Jul 2;16(7):1728-1737. doi: 10.1080/21645515.2020.1769388. Epub 2020 Jun 23.
Over the past few years, many innovative vaccines became available that offer protection for diseases which have never been prevented before. While there are several factors that could have an impact on access, the use of health technology assessment (HTA) undoubtedly is also one of the contributing factors. : To explore the landscape of vaccine access and the role of HTA in new vaccine adoption in Association of Southeast Asian Nations (ASEAN) countries. : A great deal of progress has been made in terms of access to new and innovation vaccine in the region. Variation in access to these vaccines comparing between countries, however, is still observed. The use of HTA in supporting new vaccine adoption is still in an early stage especially in Gavi, the Vaccine Alliance-eligible countries. : Improving the use of HTA evidences to support decision making could accelerate the efficient adoption of new vaccine in ASEAN region.
在过去几年中，许多创新疫苗问世，为以前从未预防过的疾病提供了保护。虽然有几个因素可能会影响疫苗的可及性，但卫生技术评估（HTA）的使用无疑也是促成因素之一。：探索东南亚国家联盟（东盟）国家疫苗可及性的情况以及HTA在新疫苗采用中的作用。：该地区在新的创新疫苗可及性方面取得了很大进展。然而，各国之间在这些疫苗的可及性方面仍存在差异。HTA在支持新疫苗采用方面仍处于早期阶段，特别是在符合疫苗免疫全球联盟（Gavi）条件的国家。：提高HTA证据的使用以支持决策制定，可以加速东盟地区新疫苗的有效采用。
